A case and literature review of complicated gastrointestinal stromal tumors

Gastroenterology and Hepatology

Volumn 4, Issue 9, 2008, Pages 650-657

  Kale, Santosh S ^a   Sachdev, Mankanwal S ^b   Ismail, Mohammad K ^b   Davila, Rene ^b   Tombazzi, Claudio R ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LAPAROTOMY; MELENA; TUMOR BIOPSY;

EID: 53849131704     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.
2. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000;15:1293-1301.
3. Raut CP, Posner M, Desai J, Morgan JA, George S, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325-2331.
4. Antonioli DA. Gastrointestinal autonomic nerve tumors. Expanding the spectrum of gastrointestinal stromal tumors. Arch Pathol Lab Med. 1989;113:831-833.
5. Appelman HD. Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know. Am J Surg Pathol. 1986;10(suppl 1):83-99.
6. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 2001;54:96-102.
7. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-1269.
8. Huizinga JD, Berezin I, Chorneyko K, Thuneberg L, Sircar K, et al. Interstitial cells of Cajal: pacemaker cells? Am J Pathol. 1998;153:2008-2011.
9. Rumessen JJ, Mikkelsen HB, Qvortrup K, Thuneberg L. Ultrastructure of interstitial cells of Cajal in circular muscle of human small intestine. Gastroenterology. 1993;104:343-350.
10. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999;23:377-389.
11. Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int. 2006;56:1-9.
12. Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. Curr Opin Oncol. 2006;18:386-395.
13. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
14. Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology. 1998;115:1090-1095.
15. Raut CP, Morgan JA, Ashley SW. Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. Curr Opin Gastroenterol. 2007;23:149-158.
16. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol. 2006;59:557-563.
17. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813-3825.
18. De Giorgi U. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors [comment]. J Clin Oncol. 2007;25:1146-1147; author reply 1147-1148.
19. De Giorgi U, Verweij J. Imatinib and gastrointestinal stromal tumors: Where do we go from here? Mol Cancer Ther. 2005;4:495-501.
20. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-495.
21. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33:459-465.
22. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997;79:2125-2131.
23. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202:623-629.
24. NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 2.2007). [Web Based] Available at http://nccn.org/professionals/ physician_gls/PDF/sarcoma.pdf. Accessed July 20, 2007.
25. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathoiogic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer. 2003;6:39-48.
26. Koh JS, Trent J, Chen L, El-Naggar A, Hunt K, et al. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol. 2004;19:565-574.
27. van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;104:1781-1788.
28. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38(suppl 5):S37-S38.
29. Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244:176-184.
30. DeMatteo RP, Maki RG, Antonescu C, Brennan MF. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg. 2003;40:144-193.
31. Chan JK. Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Adv Anat Pathol. 1999;6:19-40.
32. Miettinen M, Virolainen M, Maarit Sarlomo R. Gastrointestinal stromal tumors - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol. 1995;19:207-216.
33. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566-578.
34. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001;8:50-59.
35. Caletti G, Zani L, Bolondi L, Brocchi E, Rollo V, Barbara L. Endoscopic ultrasonography in the diagnosis of gastric submucosal tumor. Gastrointest Endosc. 1989;35:413-418.
36. Akahoshi K, Sumida Y, Matsui N, Oya M, Akinaga R, et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine needle aspiration. World J Gastroenterol. 2007;13:2077-2082.
37. Okubo K, Yamao K, Nakamura T, Tajika M, Sawaki A, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of gastrointestinal stromal tumors in the stomach. J Gastroenterol. 2004;39:747-753.
38. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11:465-475.
39. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898-3905.
40. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest. 1998;78:1633-1636.
41. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999;59:4297-4300.
42. Yan H, Marchettini P, Acherman YI, Gething SA, Brun E, Sugarbaker PH. Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol. 2003;26:221-228.
43. Eisenberg BL. Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials. Clin Colorectal Cancer. 2006;6(suppl 1):S24-S29.
44. Besana-Ciani I, Boni L, Dionigi G, Benevento A, Dionigi R. Outcome and long term results of surgical resection for gastrointestinal stromal tumors (GIST). Scand J Surg. 2003;92:195-199.
45. Carboni F, Carlini M, Scardamaglia F, Santoro E, Boschetto A, et al. Gastrointestinal stromal tumors of the stomach. A ten-year surgical experience. J Exp Clin Cancer Res. 2003;22:379-384.
46. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg. 2003;90:332-339.
47. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001;136:383-389.
48. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery. 2003;134:656-665; discussion 665-656.
49. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
50. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-1134.
51. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg. 2003;186:665-669.
52. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14-24.
53. Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005;117:316-325.
54. Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. 2006;93:304-311.
55. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23:3999-4006.
56. Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y, Hatakeyama K. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer. 2004;90:2059-2061.
57. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
58. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003;9:5465-5476.